

CLAIMS

What is claimed is:

1. (Original) A method of treatment of animals suffering from retroviral infections comprising administering to the animal a disease mitigating amount of a detoxified modified venom composition containing alpha-neurotoxins.

2. (Original) The method of claim 1 wherein the detoxified modified composition comprises a fraction of the whole venom containing the alpha-neurotoxins.

3. (Original) The method of claim 1 wherein the alpha-neurotoxins are selected from the group consisting of alpha-bungarotoxin, alpha-cobratoxin, alpha-cobrotoxin, alpha-conotoxins (G1, M1, S1, S1A, ImI), alpha-dendrotoxin and erabutoxin.

4. (Original) The method of claim 1 wherein the alpha-neurotoxin composition comprises alpha-cobratoxin.

5. (Original) The method of claim 1 wherein in humans a dosage of the composition ranges substantially from 0.01 to 10 ml based on a 0.1% solution of the modified cobratoxin per 150 lbs body weight.

6. (Original) The method of claim 5 wherein the dosage is from 0.2 to 2 ml.

7. (Original) The method of claim 5 wherein the dosage is administered substantially with a frequency of from every other week to daily.

8. (Original) The method of claim 5 wherein the dosage is administered at least weekly.

9. (Original) The method of claim 5 wherein the dosage is administered at least daily.

10. (Original) The method of claim 5 wherein the administration is by one of injection, orally, otically and by intradermal routes.

11. (Original) The method of claim 10 wherein administration by injection is by one of subcutaneous, intramuscular and intravenous.

12. (Original) The method of claim 1 which further comprises a viral condition benefiting from improved immunological functioning and reduced viral load.

13. (Presently Amended) The method of claim 1 wherein the retroviral infection is ~~selected from a group comprising~~ human immunodeficiency virus (HIV), ~~simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIIV).~~

14. (Original) The method of claim 10, wherein the alpha-cobratoxin is administered orally when combined in a solution with benzalkonium chloride.

15. (Original) The method of claim 10, wherein the alpha-cobratoxin is administered orally when combined in a solution with benzalkonium chloride at a protein detergent ratio of between 1:6 to 1:8, and preferably 1:7.5.